To estimate the potential clinical utility of ACTB methylation as a marker for the risk assessment of CHD, ROC curve analyses were performed adjusted for possible confounding effects by two logistic regression models (model a: adjusted for age, gender, and batch effect, and model b: adjusted for age, gender, smoking, hypertension, diabetes, TC, TG, LDL–C, and batch effect). This evidence concerns the gene ACTB and Hypertension.